SCHEMBL7929

SCHEMBL7929

CCOc1ccccc1N1CCN(CCCCOc2ccc3ccc(=O)[nH]c3c2)CC1

nearest known ligand 0.93

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 17/20 0.93
DRD3 P35462 7/20 0.79
DRD4 P21917 6/20 0.79
SLC6A2 P23975 2/20 0.65
SLC6A4 P31645 2/20 0.65
ADRA1A P35348 2/20 0.65
ADRB2 P07550 1/20 0.65
ADRB1 P08588 1/20 0.65
HTR1A P08908 1/20 0.65
ADRA2A P08913 1/20 0.65
ADRA2B P18089 1/20 0.65
ADRA2C P18825 1/20 0.65
DRD1 P21728 1/20 0.65
DRD5 P21918 1/20 0.65
ADRA1D P25100 1/20 0.65
HTR1D P28221 1/20 0.65
HTR1B P28222 1/20 0.65
HTR2A P28223 1/20 0.65
HTR2C P28335 1/20 0.65
HTR1E P28566 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL252032 0.96 DRD2 (1.00) DRD2DRD3DRD4SLC6A2SLC6A4
SCHEMBL13532791 0.91 DRD2 (0.94) DRD2DRD3DRD4SLC6A2SLC6A4
SCHEMBL10664987 0.88 DRD2 (1.00) DRD2DRD3DRD4SLC6A2SLC6A4
SCHEMBL252623 0.88 DRD2 (1.00) DRD2DRD3DRD4SLC6A2SLC6A4
SCHEMBL16559648 0.87 DRD2 (0.72) DRD2DRD3DRD4SLC6A2SLC6A4
SCHEMBL13532797 0.86 DRD2 (0.87) DRD2DRD3DRD4SLC6A2SLC6A4
SCHEMBL252902 0.86 DRD2 (1.00) DRD2DRD3DRD4SLC6A2SLC6A4
SCHEMBL15601757 0.85 DRD2 (0.69) DRD2DRD3DRD4SLC6A2SLC6A4
SCHEMBL7324533 0.84 DRD2 (0.68) DRD2DRD3DRD4SLC6A2SLC6A4
SCHEMBL20029449 0.83 DRD2 (0.71) DRD2DRD3DRD4SLC6A2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0367141-B1 Carbostyril derivatives OTSUKA PHARMA CO LTD (JP) 1996-01-10 EP claimed
US-5006528-A Carbostyril derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1991-04-09 US claimed
EP-0367141-A2 Carbostyril derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1990-05-09 EP claimed
US-20130289024-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND 2013-10-31 US disclosed
US-8475804-B2 Compositions and methods for treatment of filovirus-mediated diseases U.S. ARMY MEDICAL RESEARCH AND MATERIAL COMMAND (US) 2013-07-02 US disclosed
US-20110028564-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES ZALICUS INC. 2011-02-03 US disclosed
US-20100009983-A1 5 HT RECEPTOR MEDIATED NEUROGENESIS BRAINCELLS, INC. (US) 2010-01-14 US disclosed
US-20100009983-A1 5 HT RECEPTOR MEDIATED NEUROGENESIS BRAINCELLS, INC. (US) 2010-01-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100009983-A1 5 HT RECEPTOR MEDIATED NEUROGENESIS HTR6, GAP43, HTR5A DRD2 242/4885DRD3 432/4885DRD4 301/4885
US-20110028564-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES FLNA, FLNB, PIGS DRD2 4871/4885DRD3 4854/4885DRD4 4834/4885
US-20130289024-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES FLNA, FLNB, PIGS DRD2 4871/4885DRD3 4854/4885DRD4 4834/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.